Antiviral drug effective against coronavirus, remdesivir reveals study


Remdesivir, injected intravenously daily for 10 days, has accelerated recovery in hospitalized patients with COVID-19, a study f

Remdesivir, injected intravenously daily for 10 days, has accelerated healing in hospitalized patients with COVID-19, study finds

Remdesivir, an antiviral drug, reduces recovery times in patients with coronavirus, according to the complete results of a trial published Friday evening, three weeks after the main American expert in infectious diseases said that the study had shown that the drug had “clear” benefits.

The full results of the research, which was conducted by the US government agency the National Institute of Allergy and Infectious Diseases (NIAID), were published in the leading medical periodical on New England Journal of Medicine.

The United States authorized emergency use of remdesivir in hospitals on May 1, followed by Japan, while Europe plans to follow suit.

The study found that remdesivir, injected intravenously daily for 10 days, accelerated the recovery of hospitalized COVID-19 patients compared to placebo in clinical trials in just over a thousand patients in 10 countries.

On April 29, NIAID Director Anthony Fauci, who has become the trusted face of the US government on the coronavirus pandemic, said that preliminary evidence indicated that remdesivir had “a clear, significant and positive effect in reducing the recovery time “.

The National Institutes of Health, of which NIAID is a member, said in an online statement on Friday that investigators had found that “remdesivir was most beneficial for hospital patients with severe illness who needed additional oxygen “

But the authors of the trial wrote that the drug did not prevent all of the deaths.

“Given the high mortality despite the use of remdesivir, it is clear that treatment with an antiviral medication alone is unlikely to be sufficient,” they said.

About 7.1% of patients receiving remdesivir in the trial group died within 14 days, compared to 11.9% in the placebo group.

However, the result is just below the statistical reliability threshold, which means that it could be due to chance rather than the ability of the drug.

Follow the news of the coronavirus epidemic (COVID-19)

More information:
John H. Beigel et al. Remdesivir for the treatment of Covid-19 – Preliminary report, New England Journal of Medicine (2020). DOI: 10.1056 / NEJMoa2007764

© 2020 AFP

Remedivir, antiviral drug effective against coronavirus, reveals study (2020, May 23)
retrieved May 23, 2020

This document is subject to copyright. Apart from any fair dealing for the purpose of study or private research, no
a part can be reproduced without written authorization. The content is provided for information only.


Please enter your comment!
Please enter your name here